Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Liora M SchultzChristina BaggottSnehit PrabhuHolly L PacentaChristine L PhillipsJenna RossoffHeather E StefanskiJulie-An TalanoAmy MoskopSteven P MargossianMichael R VernerisGary Douglas MyersNicole A KarrasPatrick A BrownMuna QayedMichelle L HermistonPrakash SatwaniChrista KrupskiAmy K KeatingRachel WilcoxCara A RabikVanessa A FabrizioRayne H RouceVasant ChinnabhandarMichael KunickiValentin V BarsanA Yasemin GokseninYimei LiSharon MavroukakisEmily EgelerKevin J CurranCrystal L MackallTheodore W LaetschPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Commercial tisagenlecleucel in CAYA RR B-ALL demonstrates efficacy and tolerability. This first analysis of commercial tisagenlecleucel stratified by disease burden identifies HB preinfusion to associate with inferior OS and EFS and increased toxicity.